76.45
-0.88
(-1.14%)
May 20 - Close
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 76.31 - 77.38 |
| 52 week | 44.19 - 78.36 |
| Open | 77.15 |
| Vol / Avg. | 0.00/419,915.00 |
| Mkt cap | 4.21B |
| P/E | 39.80 |
| Div/yield | - |
| EPS | 1.92 |
| Shares | 55.12M |
| Beta | 1.14 |
| Inst. own | 97% |
Events
Jul 22, 2013
Q2 2013 Covance Earnings Release
May 15, 2013
Covance at Bank of America Merrill Lynch Health Care Conference -
May 8, 2013
Covance at Robert W Baird and Co Growth Stock Conference
May 7, 2013
Covance Annual Shareholder Meeting
May 2, 2013
Q1 2013 Covance Earnings Conference Call -
Feb 26, 2013
Covance at Citi Global Healthcare Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 7.59% | 4.00% |
| Operating margin | 7.61% | 4.59% |
| EBITD margin | - | 13.20% |
| Return on average assets | 8.51% | 4.31% |
| Return on average equity | 14.58% | 6.85% |
| Employees | 11,790 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Covance Inc. is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The services it provides constitutes two segments: early development services, which includes discovery support services, preclinical services and clinical pharmacology services, and late-stage development services, which includes central laboratory, Phase II-IV clinical development, and market access services. In 2011, Covance acquired certain assets of TRAC Microbiology, Inc., a food microbiology and chemistry laboratory.
Officers and directors
| Joseph L. Herring | Chairman of the Board, Chief Executive Officer | |
| Alison Cornell | Chief Financial Officer, Vice President | |
| Richard F. Cimino | Executive Vice President, Group President - Clinical Development | |
| Deborah L. Keller Tanner | Executive Vice President, Group President - Research and Development Laboratories | |
| William E. Klitgaard | Corporate Senior Vice President, Chief Information Officer, Treasurer | |
| James W. Lovett Esq. | Corporate Senior Vice President, General Counsel, Secretary | |
| John E. Watson | Corporate Senior Vice President, Chief Commercial Officer, President - Strategic Partnering | |
| Brian H. Nutt | Principal Accounting Officer, Director - External Reporting | |
| Gary E. Costley Ph.D. | Lead Independent Director | |
| Robert L. Barchi M.D., Ph.D. | Independent Director |